127 related articles for article (PubMed ID: 31461752)
1. [Evaluation of intratherapeutic 177Lu-HA-DOTATATE treatment in neuroendocrine tumors: dosimetry with SPECT, whole-body imaging and gamma probe].
Leonhäuser B; Happel C; Gröner D; Bockisch B; Fiebich M; Hellwig D; Grünwald F; Kranert WT
Nuklearmedizin; 2019 Sep; 58(5):379-386. PubMed ID: 31461752
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
3. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
4. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
5. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
Thakral P; Sen I; Das SS; Manda D; Cb V; Malik D
Br J Radiol; 2021 Oct; 94(1126):20210403. PubMed ID: 34357794
[TBL] [Abstract][Full Text] [Related]
7. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
8. Personalized kidney dosimetry in
Hou X; Zhao W; Beauregard JM; Celler A
Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
[TBL] [Abstract][Full Text] [Related]
9. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.
Kupitz D; Wetz C; Wissel H; Wedel F; Apostolova I; Wallbaum T; Ricke J; Amthauer H; Grosser OS
PLoS One; 2017; 12(11):e0187570. PubMed ID: 29107992
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of 177Lu Therapy Monitoring Using Fast Whole-Body SPECT Recordings Provided by a High-Speed 360° CZT Camera.
Chevalier E; Boursier C; Claudin M; Marie PY; Imbert L
Clin Nucl Med; 2020 Nov; 45(11):e493-e494. PubMed ID: 32604119
[TBL] [Abstract][Full Text] [Related]
11. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
12. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers.
Peterson AB; Wang C; Wong KK; Frey KA; Muzik O; Schipper MJ; Dewaraja YK
Clin Nucl Med; 2023 May; 48(5):393-399. PubMed ID: 37010563
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
[TBL] [Abstract][Full Text] [Related]
15. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a
Zhao W; Esquinas PL; Frezza A; Hou X; Beauregard JM; Celler A
Phys Med Biol; 2019 Aug; 64(17):175006. PubMed ID: 31287093
[No Abstract] [Full Text] [Related]
18. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
[TBL] [Abstract][Full Text] [Related]
19. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.
Sandström M; Garske U; Granberg D; Sundin A; Lundqvist H
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):212-25. PubMed ID: 19727718
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.
Delker A; Ilhan H; Zach C; Brosch J; Gildehaus FJ; Lehner S; Bartenstein P; Böning G
Mol Imaging Biol; 2015 Oct; 17(5):726-34. PubMed ID: 25790773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
